Figure 4.
HSCT-treated GC/JAK3 patients without IVIG replacement therapy have decreased IgA-coating of nasopharyngeal bacteria. (A) Representative dot plots of IgA, IgG, and IgD binding to nasopharyngeal microbiota in healthy and HSCT-treated SCID patients. (B) Percentage of IgA/IgG/IgD–coated nasopharynx microbes in healthy and HSCT-treated SCID patients. (C) Double IgA/IgG or IgA/IgD–coated nasopharynx microbes in healthy and HSCT-treated SCID patients. Panels A through C: box plots with median ± minimum to maximum. P values were determined with the Kruskal-Wallis test followed by Dunn’s posttest for multiple group comparisons; *P < .05, **P < .005, ***P < .001. FCS-W, forward scatter, width; n.s., not significant.

HSCT-treated GC/JAK3 patients without IVIG replacement therapy have decreased IgA-coating of nasopharyngeal bacteria. (A) Representative dot plots of IgA, IgG, and IgD binding to nasopharyngeal microbiota in healthy and HSCT-treated SCID patients. (B) Percentage of IgA/IgG/IgD–coated nasopharynx microbes in healthy and HSCT-treated SCID patients. (C) Double IgA/IgG or IgA/IgD–coated nasopharynx microbes in healthy and HSCT-treated SCID patients. Panels A through C: box plots with median ± minimum to maximum. P values were determined with the Kruskal-Wallis test followed by Dunn’s posttest for multiple group comparisons; *P < .05, **P < .005, ***P < .001. FCS-W, forward scatter, width; n.s., not significant.

Close Modal

or Create an Account

Close Modal
Close Modal